MorphoSys to Acquire Constellation Pharmaceuticals for ~$1.7B
Shots:
- MorphoSys to acquire all of the outstanding shares of Constellation’s common stock for $34.00/ share in cash making a total equity value of $1.7B. The transaction is expected to close in Q3’21
- The acquisition will bolster Morphosys’ position in hematology-oncology & accelerates growth strategy with the addition of Constellation’s Pelabresib (CPI-0610) & CPI-0209
- Additionally- MorphoSys enters into a strategic funding partnership with Royalty Pharma- under which MorphoSys will receive $1.425B as up front- $350M as development funding bonds- $150 as milestones. Royalty Pharma will receive royalties and is expected to invest $100M in a cash capital increase of MorphoSys
Ref: Businesswire | Image: Constellation Pharmaceuticals
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com